Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials

NCT04493424 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04493424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04493424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
September 4, 2020
Completion date
May 15, 2023
Enrollment
108 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis